A new study published in the journal Epilepsy & Behavior has demonstrated significant seizure reduction in adults with Lennox-Gastaut syndrome (LGS) using cannabidiol.
Conducted by researchers at Queen Elizabeth Hospital’s Department of Neurology, the research offers promising results for a condition known for its treatment resistance.
Epileptic encephalopathies, such as LGS, are severe childhood-onset epilepsy disorders that can severely impair cognitive and motor functions. Despite advancements in medical and surgical treatments, many patients continue to experience uncontrolled seizures. In December 2019, the National Institute for Health and Care Excellence (NICE) approved cannabidiol as an adjunctive treatment for LGS-related seizures.
Continue reading